OncoMatch/Clinical Trials/NCT06288373
Neoadjuvant Chemoimmunotherapy Versus Concurrent Chemoradiotherapy for LACC
Is NCT06288373 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2/3 trial studies multiple treatments including Camrelizumab and Cisplatin for cervical cancer.
Treatment: Camrelizumab · Cisplatin · Nab paclitaxel · Cisplatin — It is a prospective, open-label, randomized, controlled phase II/III clinical trial in which patients with PD-L1-positive FIGO stage IB3, IIA2 and IIB（tumors \>4 cm in diameter）will be enrolled and randomly divided into the neoadjuvant chemoimmunotherapy plus surgery group and the CCRT group.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Immunotherapy
Chemotherapy
Cancer type
Cervical Cancer
Biomarker criteria
Required: PD-L1 (CD274) positive expression, Combined Positive Score (CPS) ≥1 (CPS ≥1)
Positive PD-L1 expression, Combined Positive Score (CPS) ≥1
Disease stage
Required: Stage IIB
Performance status
ECOG 0–1(Restricted strenuous activity)
Demographics
Prior therapy
Cannot have received: immune checkpoint inhibitor
Prior treatment with immune checkpoint inhibitors, including but not limited to other anti-PD-1 and anti-PD-L1 antibodies
Lab requirements
Blood counts
WBC ≥ 3.5×10^9/L, NEU ≥ 1.5×10^9/L, PLT ≥ 100×10^9/L
Kidney function
serum creatinine (BUN) ≤ 1.5x ULN or creatinine clearance ≥ 50 mL/min
Liver function
total bilirubin ≤ 1.5x ULN; ALT and AST ≤ 1.5x ULN
Laboratory tests: WBC (white blood cell count) ≥ 3.5×109/L, NEU (neutrophil count) ≥ 1.5×109/L, PLT (platelet count) ≥ 100×109/L, total bilirubin ≤ 1.5 times the upper limit of normal, ALT (alanine aminotransferase) and AST (aspartate aminotransferase) ≤ 1.5 times the upper limit of normal, serum creatinine (BUN) ≤ 1.5 times the upper limit of normal or creatinine clearance ≥ 50 mL/min
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06288373 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior immune checkpoint inhibitor disqualifies patients from enrollment.
Does this trial require CD274?
Yes, CD274 positive expression, Combined Positive Score (CPS) ≥1 is a required biomarker for enrollment.
What disease stage is eligible?
Stage IIB is required.
Is there an age limit?
Yes. Patients must be 70 years or younger.
Is this trial open to male patients?
No. This trial enrolls female patients only.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages